Gradientech’s core product is QuickMIC, an ultra-rapid AST device designed to deliver fast, precise antibiotic susceptibility and dosage guidance. The system is already being implemented in several European hospitals. Gradientech has initiated a 510(k) study in the U.S. as a step toward regulatory approval and broader adoption in North America. On October 8, 2024, the company announced an exclusive commercialization partnership with Hardy Diagnostics for the United States and Canada. The collaboration pairs Gradientech’s technology with Hardy’s established North American microbiology distribution network and clinical expertise. Financially, Hardy purchased 1,796,571 shares in Gradientech for approximately SEK 31.4 million, increasing Gradientech’s share capital and strengthening its balance sheet for growth.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2024